|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
HPV 16 and/or 18 were detected in 156 (80%) tumors. p16 was positive in 186 (96%) carcinomas, but eight tumors (4%) were negative for p16 (seven squamous cell carcinomas, one adenocarcinoma); 5/8 caused by HPV 16 and/or 18.
|
31492932 |
2020 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88).
|
31157548 |
2019 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Immunocytochemical studies on PF cell blocks allow: (a) to distinguish mesothelioma from reactive mesothelial proliferations (e.g. loss of BAP1 nuclear expression, complemented by the demonstration of p16 deletion using fluorescence in situ hybridization, indicate mesothelioma); (b) to separate mesothelioma from adenocarcinoma (e.g. calretinin, CK 5/6, WT-1 and D2-40 are markers of mesothelioma, whereas CEA, EPCAM, TTF-1, napsin A, and claudin 4 are markers of carcinoma); and (c) to reveal tumor origin in pleural metastases of an unknown primary site (e.g.
|
30354850 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Most endocervical adenocarcinomas are human papillomavirus (HPV)-related cancers associated with p16 immunostaining.
|
31014281 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stromal p16 expression was evaluated in endocervical adenocarcinomas, including usual-type endocervical adenocarcinoma (UEA), intestinal-type mucinous carcinoma (MC-I), and MC-G.
|
29848709 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
E6, p53 and p16 demonstrated significantly different expression levels in squamous epithelial tissue compared with adenocarcinomas.
|
29085443 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Positive reactivity for p16 was significantly associated (P=0.001) with histological grade, and was more commonly expressed in squamous cell carcinoma than adenocarcinomas.
|
28454340 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Synchronous lung cancers from 60 patients (42 with adenocarcinoma and 18 with squamous cell carcinoma), clinically considered to represent intrapulmonary metastases, were histologically subtyped according to the 2015 World Health Organization classification of lung tumors and subjected to genotypic analysis (KRAS, EGFR, BRAF, PIK3CA, ALK, MET and ROS1 in adenocarcinoma and PIK3CA and p16 in squamous cell carcinoma).
|
27080983 |
2016 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We used gene expression data and immunohistochemistry to examine cyclin D1 and p16 levels in patient-derived xenografts (PDX), and prostatic small-cell carcinoma and adenocarcinoma specimens.
|
26246306 |
2015 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
All the GNAS-mutated LEGHs were negative for HPV DNA and p16 expression, whereas all the GNAS-mutated adenocarcinomas were positive for HPV DNA and/or p16 expression, implicating GNAS mutations in the development of LEGH and a minor subset of HPV-related cervical adenocarcinomas.
|
24145653 |
2014 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The goal of this study was to investigate p53 and p16 expression, as well as HPV status, in a relatively large series of primary bladder adenocarcinomas.
|
24752337 |
2014 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We investigated the presence of HPV genome by in situ hybridization (ISH) and polymerase chain reaction (PCR) and P16 or Rb protein expression by immunohistochemistry (IHC) in 336 surgically resected primary NSCLC: 204 adenocarcinoma (AdC) and 132 squamous cell carcinoma (SqCC).
|
23254264 |
2013 |
|
Adenocarcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
In multivariate analysis, p16 hypermethylation was more prevalent in lung tumours from male than female patients (P = 0.018) and in squamous cell carcinomas than in adenocarcinomas (P = 0.025).
|
22217548 |
2012 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of p16 expression was associated with poorer survival time for the entire cohort and for certain subgroups including men, age younger than 65 years, smokers, early tumor stage, adenocarcinoma, and large-cell carcinoma.
|
21857254 |
2011 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Sixty-three cervical adenocarcinomas, comprising those of usual type (n = 43), minimal deviation type (n = 4), gastric type (n = 3), intestinal type (n = 3), mesonephric type (n = 3), clear cell type (n = 4), serous type (n = 2) and hepatoid type (n = 1) underwent linear array HPV genotyping and immunohistochemistry for p16.
|
20727021 |
2010 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Methylation levels of the p16 promoter were significantly higher in squamous cell carcinoma than in adenocarcinoma (p = 0.020).
|
19795445 |
2010 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Distinction of serous carcinomas from endocervical adenocarcinomas (HPV-related type), both of which share diffuse p16 expression and frequently lack hormone receptor expression, relies on morphology and diffuse/strong p53 expression in the former and detection of HPV in the latter.
|
19623034 |
2009 |
|
Adenocarcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Our results indicate that Por tumorigenesis strongly correlates with MSI and methylation of the p16 and hMLH1 promoter region.
|
18161865 |
2008 |
|
Adenocarcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
When we considered histological type, we observed that p16 promoter methylation was significantly higher in squamous cell carcinomas (30/33, 91%) compared with adenocarcinomas (21/30, 70%) (p=0.029).
|
18449464 |
2007 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The purpose of this investigation was to determine whether genes in addition to p16 are "targeted" for silencing and whether overall gene methylation was more common in radiation-induced adenocarcinoma.
|
17903034 |
2007 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerical alterations of chromosome 9, the status of promoter methylation and protein expression of the CDKN2A gene (aliases include p16 and p16(INK4a)), the possible association with gain of chromosome X, and the interrelation of these findings with clinic and pathological characteristics were investigated in gastric adenocarcinomas.
|
17981214 |
2007 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The immunohistochemical expression pattern of p16 in biopsy samples has been useful as part of a panel to distinguish adenocarcinomas arising from the endometrium from those arising from the endocervix.
|
17581420 |
2007 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical expression of p16 was assessed in 195 tumors, including 98 primary ovarian tumors (51 mucinous, 47 endometrioid, and 4 mixed mucinous-endometrioid tumors), 93 metastatic adenocarcinomas of known primary sites (colorectum: 34, endocervix: 19, pancreaticobiliary tract: 17, appendix: 7, stomach: 5), 11 metastatic adenocarcinomas of unknown origin (7 established as noncervical), and 4 adenocarcinomas of uncertain (primary ovarian vs. metastatic) origin.
|
17460447 |
2007 |
|
Adenocarcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Aberrant methylations of p16INK4a and p14ARF gene were present in 21 (32.3%) and 33 (50.8%) out of 65 cases, respectively. p16INK4a aberrant methylation was correlated with p16 negativity (P=0.021) and p53 overexpression (P=0.007). p16INK4a aberrant methylation was more frequently present in poorly differentiated adenocarcinomas (P=0.002).
|
16675157 |
2006 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
|
16462152 |
2006 |